zebutinib + bendamustine + rituximab or zebutinib + fludarabine + cyclophosphamide + rituximab

This entry refers to two alternative multi-drug chemotherapy regimens used in the treatment of B-cell malignancies, particularly lymphomas and chronic lymphocytic leukemia. Both regimens are combinations of targeted therapy and cytotoxic agents: - **zebutinib** is a small molecule Bruton tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling, leading to reduced proliferation and survival of malignant B cells. - **bendamustine** is an alkylating agent that causes DNA crosslinking and cell death. - **rituximab** is a monoclonal antibody targeting CD20 on B cells, inducing cell lysis via immune-mediated mechanisms. - **fludarabine** is a purine analog that inhibits DNA synthesis. - **cyclophosphamide** is an alkylating agent causing DNA damage. The first regimen combines zebutinib with bendamustine and rituximab; the second combines zebutinib with fludarabine, cyclophosphamide, and rituximab. These regimens are designed for synergistic anti-tumor activity by combining targeted BTK inhibition with immunotherapy (anti-CD20) and cytotoxic chemotherapy. They are typically used in relapsed/refractory or high-risk cases where standard therapies may be less effective.